CoChat

Loss of Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Were Receiving Initial Metformin, Sulfonylurea, or Thiazolidinedione Monotherapy

Riedel, Aylin A., Heien, Herbert, Wogen, Jenifer, Plauschinat, Craig A. · 2007 · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Cited by 77

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Study Objectives. To examine glycosylated hemoglobin (A1C) values longitudinally in patients who newly started metformin, sulfonylurea, or thiazolidinedione monotherapy; in a subset of patients whose A1C values were 7% or greater before starting therapy (baseline) and who achieved A1C goal (A1C < 7%) during therapy, rates of secondary failure (i.e., A1C value returned to ≥ 7% during therapy) were compared for each drug. Design. Four‐year retrospective analysis. Data Source. Administrative database from a large health care plan. Patients. Patients who filled at least one prescription for metformin (5453 patients), sulfonylurea (2373), and thiazolidinedione (1590) therapy, respectively, between January 1, 2001, and March 31, 2004, were enrolled. Measurements and Main Results. Patients' demographic and clinical characteristics, baseline A1C values, changes in A1C values (last available result during follow‐up minus baseline value), and A1C values before and after the addition of an antidiabetic drug other than the index drug (therapy intensification) were documented. Mean age was 50.7 years; 5027 (53.4%) were men. Mean baseline A1C value was 8.4%, and about 70% of patients had an AIC value of 7% or greater before starting therapy. Mean follow‐up was 1.9 years, and mean decrease in A1C values was 1.47% (to 6.91%). The probabilities of attaining A1C goals were similar for patients receiving metformin, sulfonylurea, or thiazolidinedione therapy. The rate of therapy intensification among patients taking metformin (24.7%) was lower than that of patients taking a sulfonylurea (30.1%, p<0.001) but similar to that of those taking a thiazolidinedione (24.6%). Secondary failure occurred in 36.3% of patients; mean time from the start of therapy to its failure was about 1.51 years. Patients receiving a sulfonylurea were 1.25 (95% confidence interval [CI] 1.05–1.50) times more likely than patients receiving metformin to experience secondary failure, whereas failure rates were similar for thiazolidinediones and metformin (odds ratio 0.78, 95% CI 0.62–0.99). Conclusion. In the subset of patients assessed for secondary failure, although treatment initially reduced A1C values, more than one third experienced failure. Real‐world studies of A1C goal attainment must follow patients on a long‐term basis to assess the maintenance of glycemic control over time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1592/phco.27.8.1102

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 77

Metadata

Authors
Riedel, A. A., Heien, H., Wogen, J., & Plauschinat, C. A.
Venue
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Publisher
Wiley
Published
2007-08
Volume
27
Issue
8
Pages
1102-1110
ISSN
  • 0277-0008 (ISSN-L)
  • 1875-9114
OpenAlex
W2169715407
Cited by
77
References
5
FWCI
3.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Loss of Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Were Receiving Initial Metformin, Sulfonylurea, or Thiazolidinedione Monotherapy. https://app.cochat.ai/papers/10.1592/phco.27.8.1102
The paper
Riedel, A. A., Heien, H., Wogen, J., & Plauschinat, C. A. (2007). Loss of Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Were Receiving Initial Metformin, Sulfonylurea, or Thiazolidinedione Monotherapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.27.8.1102

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.